-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$26.00203.38% Upside
EyePoint Pharmaceuticals, Inc. Frequently Asked Questions
-
What analysts cover EyePoint Pharmaceuticals, Inc.?
EyePoint Pharmaceuticals, Inc. has been rated by research analysts at H.C. Wainwright, Mizuho Securities in the past 90 days.